MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)

Eric Van Cutsem; Heinz-Josef Lenz; Junji Furuse; Josep Tabernero; Volker Heinemann; Tatsuya Ioka; Igor Bazin; Makoto Ueno; Tibor Csõszi; Harpreet Wasan; Bohuslav Melichar; Petr Karasek; Teresa Mercade Macarulla; Carmen Guillen; Ewa Kalinka-Warzocha; Zsolt Horvath; Hans Prenen; Michael Schlichting; Ayman Ibrahim; Johanna C. Bendell

doi:10.1200/JCO.2016.34.15_suppl.4007

Back

MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)

Journal article

Peer reviewed

MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)

Eric Van Cutsem, Heinz-Josef Lenz, Junji Furuse, Josep Tabernero, Volker Heinemann, Tatsuya Ioka, Igor Bazin, Makoto Ueno, Tibor Csõszi, Harpreet Wasan, …

Journal of clinical oncology, Vol.34(15_suppl), pp.4007-4007

20/05/2016

DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.4007

Abstract

Abstract only

Metrics

1 Record Views

See more details

Details

Title: MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)
Creators - without role: Eric Van Cutsem - University Hospitals Leuven Leuven, Belgium.
Heinz-Josef Lenz - University of Southern California
Junji Furuse - Kyorin University
Josep Tabernero - Vall d'Hebron Hospital Universitari
Volker Heinemann - Ludwig-Maximilians-Universität München
Tatsuya Ioka - Osaka Medical Center for Cancer and Cardiovascular Diseases
Igor Bazin - Russian Cancer Research Center NN Blokhin
Makoto Ueno - Kanagawa Prefectural Hospital Organization
Tibor Csõszi - Jász-Nagykun Szolnok Megyei Hetényi Géza Kórház-Rendelointézet, Szolnok, Hungary;
Harpreet Wasan - Hammersmith Hospital
Bohuslav Melichar - Palacký University Olomouc
Petr Karasek - Masaryk Memorial Cancer Institute
Teresa Mercade Macarulla - Vall d'Hebron Institute of Oncology
Carmen Guillen - Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain
Ewa Kalinka-Warzocha - Lublin Oncology Center
Zsolt Horvath - University of Debrecen
Hans Prenen - KU Leuven
Michael Schlichting - Merck
Ayman Ibrahim - Ono Pharmaceutical
Johanna C. Bendell - Sarah Cannon
Publication Details: Journal of clinical oncology, Vol.34(15_suppl), pp.4007-4007
Identifiers: 9921684508331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article